<DOC>
	<DOCNO>NCT00813202</DOCNO>
	<brief_summary>The present study open-label , uncontrolled , multi-centered phase III clinical trial evaluation efficacy ( clinical efficacy hemodynamics ) safety nesiritide .</brief_summary>
	<brief_title>An Open-label , One-arm , Study Evaluate Hemodynamic Changes Safety Nesiritide Acute Decompensated Heart Failure</brief_title>
	<detailed_description>This open-label , uncontrolled , multi-centered phase II clinical trial evaluation clinical efficacy hemodynamics safety nesiritide . The study conduct hospital setting patient exhibit symptom acute decompensated heart failure , require treatment intravenous drug administration . The total duration 180 day , include screen phase , open treatment phase ( 24 hour ) safety follow-up phase ( day 30 day 180 ) . Screening phase : Right heart float catheter place patient acute decompensate heart failure meet inclusion criterion exclusion criterion measure pulmonary capillary wedge pressure . The result =20 mmHg . Open treatment phase : Nesiritide administer intravenous injection dose 2 µg/kg 60 second , follow intravenous infusion dose 0.01 µg/kg 24 hour . All patient monitor hemodynamics 24 hour . Safety follow-up phase : On day 30 , patient require return study center follow-up . Information death , severe adverse event , re-hospitalization serum creatinine collect . On day 180 , patient follow telephone . Information death severe adverse event collect . Pulmonary capillary wedge pressure measure 15 minute , 1 hour , 3 hour 24 hour , compare baseline value . Nesiritide white off-white sterile lyophilize lump powder , supply transparent 5 mL glass vial . The investigational drug administer via infusion pump . Infusion rate adjust accord body weight . The drug administer directly via venous cannula near injection port venous cannula 60 second . The dosage nesiritide 2 µg/kg . The infusion rate nesiritide adjust 0.01 µg/kg/min ( exceed 0.01 µg/kg/min ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Systolic blood pressure &gt; 90 mmHg The subject must present dyspnoea rest state minimum activity amount ( stand ) Onset time complicate symptom acute decompensate heart failure , serious enough call hospitalization treatment intravenous drug administration Acute decompensate heart failure cause cardiogenic factor rather pulmonary factor ( example , neither cor pulmonale chronic heart failure complicate pneumonia ) The patient must least two manifestation related acute onset . Patients systolic blood pressure =90 mmHg patient administer intravenous nitroglycerin intravenous vasoactive drug within 2 hour administration investigational drug Patients know suspected acute coronary syndrome ( Myocardial infarction without increase ST segment , unstable myocardial infarction ) within 2 week administration investigational drug Patients cardiac shock clinical manifestation uncorrected hypovolemia sodium depletion ( clinical sign excessive diuresis dehydration ) , clinical manifestation induce forbidden venous vasoactive agent Patients extremely emergent unstable clinical condition tolerant SwanGanz catheter temporal baseline evaluation patient obvious cardiac valvular stenosis ( subject treat valvereplacement include ) , hypertrophic , restrictive , obstructive myocardial disease , primary pulmonary hypertension , complex congenital heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Nesiritide</keyword>
	<keyword>Natrecor</keyword>
	<keyword>Quanke</keyword>
	<keyword>Acute Decompensated Heart Failure</keyword>
</DOC>